生物原始喘患者的临床缓解:日本的一项多中心研究
Keiji Oishi1, Kazuki Hamada1, Ayumi Fukatsu-Chikumoto1
1Department of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, Ube, Japan.
The journal of allergy and clinical immunology. In practice
|November 8, 2024
概括
在使用吸入性皮质类固醇/长效β2抗原剂 (ICS/LABA) 治疗的喘患者中实现临床缓解 (CR) 是具有挑战性的. 关于控制喘的医生和患者的分歧显著阻碍了达到CR.
科学领域:
- 肺部病理学 肺部病理学
- 喘管理 喘管理
- 临床研究 临床研究
背景情况:
- 临床缓解 (CR) 是一种新兴的,可实现的治疗目标,用于所有严重程度的喘患者.
- 标准疗法包括吸入性皮质类固醇/长效β2激动剂 (ICS/LABA) 和非生物治疗.
研究的目的:
- 为了确定在没有生物药物的ICS/LABA上喘患者的CR实现率.
- 确定与实现CR相关的患者特征.
主要方法:
- 在日本进行了一项多中心,横截面调查的后期分析.
- 定义了三通路CR (没有恶化,没有口服皮质类固醇,控制症状),四通路CR (3通路CR + 正常化肺功能) 和深度缓解 (4通路CR + 抑制的呼吸道炎症).
- 使用喘控制问卷,%FEV1和FeNO水平来评估CR标准.
主要成果:
- 三路CR,四路CR和深度缓解的比率分别为56.9%,35.0%和24.7%.
- 没有达到三通路CR的患者的FEV1比例较低,FeNO水平较高.
- 关于喘控制的医生-患者感知差异在没有达到CR的患者中 (38.5% vs 9.3%) 和独立预测的未能实现三向CR的患者中更为常见.
结论:
- 在没有生物药物的情况下,通过ICS/LABA实现临床缓解具有重大挑战.
- 患者和医生之间感知到的喘控制方面的差异是实现CR的主要障碍.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
237
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
237
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
96
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
96
01:26Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K